Lenalidomide + Rituximab: First Line in Mantle Cell LymphomaLenalidomide + Rituximab: First Line in Mantle Cell Lymphoma

The combination lenalidomide and rituximab shows promise as frontline therapy in mantle cell lymphoma, but larger trials and longer follow-up are needed. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news